Julie Zulkosky
Psychiatric/Mental Health · Omaha, NENPI 1184214801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,450, 3.2 times the $761 reported in 2021. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$943
- Johnson & Johnson$626
- Supernus Pharmaceuticals, Inc.$589
- Alkermes, Inc.$493
- plus $3K from 22 others
What the payments were for
- Food & beverage$8,24398%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $1,702 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $1,212 |
| Otsuka America Pharmaceutical, Inc. | 65 | $943 |
| Johnson & Johnson | 31 | $626 |
| Supernus Pharmaceuticals, Inc. | 32 | $589 |
| Alkermes, Inc. | 29 | $493 |
| Lundbeck LLC | 24 | $433 |
| Vanda Pharmaceuticals Inc. | 23 | $400 |
| Axsome Therapeutics, Inc. | 26 | $356 |
| Novo Nordisk | 6 | $194 |
| Tris Pharma Inc | 9 | $192 |
| Teva Pharmaceuticals USA, Inc. | 10 | $189 |
| Corium, LLC | 8 | $150 |
| Neos Therapeutics, LP | 13 | $149 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Noven Therapeutics, LLC | 7 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Almatica Pharma LLC | 5 | $91 |
| Idorsia Pharmaceuticals US Inc | 5 | $81 |
| Adlon Therapeutics L.p. | 3 | $56 |
| Merck | 4 | $53 |
| Collegium Pharmaceutical, Inc. | 3 | $52 |
| Neuronetics, Inc. | 1 | $31 |
| Bausch Health US, LLC | 1 | $22 |
| Harmony Biosciences LLC | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Brainsway USA Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,437 in reported general payments places this provider in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 96 | $133,340 |
| VraylarCariprazine Hcl | 33 | $54,181 |
| BelsomraSuvorexant | 13 | $5,938 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 66 | $2,436 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,436 |
| Vilazodone Hcl | 11 | $1,121 |
| Duloxetine Hcl | 32 | $1,011 |
| Lurasidone Hcl | 19 | $572 |
| Atomoxetine Hcl | 11 | $519 |
| Clonazepam | 26 | $353 |
| Bupropion XlBupropion Hcl | 15 | $301 |
| Fluoxetine Hcl | 18 | $289 |
| Lamotrigine | 24 | $233 |
| Diazepam | 17 | $226 |
| Buspirone Hcl | 24 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $626 | $133,34096 claims |
| AbbVieVraylar | $1,702 | $54,18133 claims |
| MerckBelsomra | $53 | $5,93813 claims |
| Almatica Pharma LLCSertraline Hcl | $91 | $4518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
- Heather WilhelmOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.